Featured News

COMPANY

Q&A: UVA-Trained Biotech Leader Setting Her Sights on Lupus

Q&A: UVA-Trained Biotech Leader Setting Her Sights on Lupus

CLICK TO READ ORIGINAL ARTICLE > by Fariss Samarrai, farisss@virginia.edu Lupus is a complex autoimmune disease that affects more than 1.4 million Americans. Its treatment in the United States alone costs about $7 billion per year. Despite this impact and cost, the...

read more
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee

Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee

Virginia Catalyst Awards $2 Million in Grants to Support Life Sciences in the Commonwealth. Four collaborative projects involving Virginia research universities and industry partners selected to address major unmet healthcare needs, drive job creation and capital formation in Virginia.

read more

PLATFORM

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

PRODUCTS

Experimental Blood Test Could Improve Fibromyalgia Treatment

Experimental Blood Test Could Improve Fibromyalgia Treatment

A small pilot study suggests an experimental blood test for fibromyalgia – called FibroGENE — could be used to determine which drug works best for each patient. Researchers at AMPEL BioSolutions and Duke University Medical Center found genetic biomarkers in the blood cells of 18 lupus patients with fibromyalgia-like symptoms.

read more
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples.

read more
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans.  The application of AMPEL’s genomic approach to fibromyalgia could also assist pharmaceutical companies in drug development and clinical trials. 

read more
Local company unveils blood test to find treatments for chronic pain

Local company unveils blood test to find treatments for chronic pain

A medical discovery has been made in Charlottesville that may help people who experience chronic pain, fatigue and brain fog. “This is a big problem. This is a clinical problem that is not addressed. And it’s a problem that tends to discount patients,” said CEO and Chief Medical Officer Peter Lipsky.

read more

PARTNERS

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Pin It on Pinterest